Megan D. Bailey's most recent trade in Laboratory Corp. Of America Holdings was a trade of 4,083 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 4,083 | 4,813 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 4,083 | 3,173 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.65 per share. | 01 Apr 2025 | 1,546 | 3,267 (0%) | 0% | 232.7 | 359,677 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 204 | 3,471 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 204 | 2,969 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Payment of exercise price or tax liability using portion of securities received from the company at price $ 232.65 per share. | 01 Apr 2025 | 68 | 3,403 (0%) | 0% | 232.6 | 15,820 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 3,700 | 3,700 | - | - | Non-qualified Stock Options | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 1,210 | 7,256 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 224 | 770 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 224 | 6,113 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 180 | 616 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 180 | 6,337 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Payment of exercise price or tax liability using portion of securities received from the company at price $ 246.27 per share. | 06 Feb 2025 | 85 | 685 (0%) | 0% | 246.3 | 20,933 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.74 per share. | 06 Feb 2025 | 70 | 546 (0%) | 0% | 247.7 | 17,342 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 67 | 752 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 67 | 6,046 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Payment of exercise price or tax liability using portion of securities received from the company at price $ 246.27 per share. | 06 Feb 2025 | 22 | 730 (0%) | 0% | 246.3 | 5,418 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Pres, Central Labs & Intl | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2024 | 1,110 | 6,517 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 205 | 505 (0%) | 0% | - | Common Stock | |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 205 | 5,407 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 216.35 per share. | 01 Apr 2024 | 69 | 436 (0%) | 0% | 216.3 | 14,928 | Common Stock |
| Labcorp | Megan Bailey D. | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 1,700 | 1,700 | - | - | Non-qualified Stock Options | |
| Labcorp | Megan Bailey D. | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 540 | 5,903 | - | - | Restricted Stock Unit | |
| Labcorp | Bailey Megan D. | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 224 | 5,679 | - | - | Restricted Stock Unit | |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 224 | 346 (0%) | 0% | - | Common Stock | |
| Labcorp | Bailey D. Megan | EVP, Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.71 per share. | 06 Feb 2024 | 87 | 259 (0%) | 0% | 223.7 | 19,463 | Common Stock |
| Labcorp | D. Megan Bailey | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 67 | 326 (0%) | 0% | - | Common Stock | |
| Labcorp | D. Bailey Megan | EVP, Chief Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 67 | 5,612 | - | - | Restricted Stock Unit | |
| Labcorp | D. Bailey Megan | EVP, Chief Strategy Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.69 per share. | 06 Feb 2024 | 26 | 300 (0%) | 0% | 223.7 | 5,816 | Common Stock |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 600 | 600 | - | - | Non-qualified Stock Options | |
| Labcorp | Megan D. Bailey | EVP, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 180 | 4,807 | - | - | Restricted Stock Unit |